Patents by Inventor Charles H. Sherwood
Charles H. Sherwood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11541075Abstract: A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.Type: GrantFiled: August 26, 2020Date of Patent: January 3, 2023Inventors: Tamera B. Gooding, Stephen J. Kennedy, Charles H. Sherwood
-
Publication number: 20210213043Abstract: A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.Type: ApplicationFiled: August 26, 2020Publication date: July 15, 2021Applicant: Anika Therapeutics, Inc.Inventors: Tamera B. Gooding, Stephen J. Kennedy, Charles H. Sherwood
-
Publication number: 20190183920Abstract: A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.Type: ApplicationFiled: July 20, 2018Publication date: June 20, 2019Inventors: Tamera B. Gooding, Stephen J. Kennedy, Charles H. Sherwood
-
Publication number: 20160082038Abstract: A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.Type: ApplicationFiled: July 24, 2015Publication date: March 24, 2016Inventors: Tamera B. GOODING, Stephen J. KENNEDY, Charles H. SHERWOOD
-
Patent number: 8323617Abstract: A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.Type: GrantFiled: June 21, 2011Date of Patent: December 4, 2012Assignee: Anika Therapeutics, Inc.Inventors: Tamera B. Gooding, Stephen J. Kennedy, Charles H. Sherwood
-
Patent number: 8124120Abstract: Disclosed are hyaluronic acid (HA) compositions including crosslinked, water-insoluble, hydrated HA gel particles. Also disclosed are methods of making the HA compositions, and methods of using the HA composition to augment tissue in a subject.Type: GrantFiled: December 22, 2003Date of Patent: February 28, 2012Assignee: Anika Therapeutics, Inc.Inventors: Khalid K. Sadozai, Tamera B. Gooding, Kyle Bui, Charles H. Sherwood
-
Publication number: 20110312912Abstract: A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.Type: ApplicationFiled: June 21, 2011Publication date: December 22, 2011Applicant: ANIKA THERAPEUTICS, INC.Inventors: Tamera B. GOODING, Stephen J. KENNEDY, Charles H. SHERWOOD
-
Patent number: 6884788Abstract: The present invention relates to biscarbodiimides, thiourea derivatives, urea derivatives, and cross-linked hyaluronan derivatives having at least one intramolecular disulfide bond, and methods of preparation thereof. The invention also includes thiolated hyaluronan derivatives and salts thereof having at least one pendant thiol group or a modified pendant thiol group, and methods of preparation thereof. An example of a modified pendant thiol group is a sulfhydryl group linked to a small molecule such as a bioactive agent, for example a drug or pharmaceutically active moiety. A hyaluronan derivative having a sulfhydryl group linked to a pharmaceutically active moiety is useful as a sustained or controlled release drug delivery vehicle. Compositions containing the hyaluronan derivatives of the invention can reversibly viscosify in vivo or in vitro, in response to mild changes in condition, and are thus useful in ophthalmic surgery and in tissue engineering.Type: GrantFiled: August 14, 2003Date of Patent: April 26, 2005Assignee: Anika Therapeutics, Inc.Inventors: Paul C. A. Bulpitt, Charles H. Sherwood, Khalid K. Sadozai
-
Publication number: 20040038934Abstract: The present invention relates to biscarbodiimides, thiourea derivatives, urea derivatives, and cross-linked hyaluronan derivatives having at least one intramolecular disulfide bond, and methods of preparation thereof. The invention also includes thiolated hyaluronan derivatives and salts thereof having at least one pendant thiol group or a modified pendant thiol group, and methods of preparation thereof. An example of a modified pendant thiol group is a sulfhydryl group linked to a small molecule such as a bioactive agent, for example a drug or pharmaceutically active moiety. A hyaluronan derivative having a sulfhydryl group linked to a pharmaceutically active moiety is useful as a sustained or controlled release drug delivery vehicle. Compositions containing the hyaluronan derivatives of the invention can reversibly viscosify in vivo or in vitro, in response to mild changes in condition, and are thus useful in ophthalmic surgery and in tissue engineering.Type: ApplicationFiled: August 14, 2003Publication date: February 26, 2004Applicant: Anika Therapeutics, Inc.Inventors: Paul C. A. Bulpitt, Charles H. Sherwood, Khalid K. Sadozai
-
Patent number: 6620927Abstract: The present invention relates to biscarbodiimides, thiourea derivatives, urea derivatives, and cross-linked hyaluronan derivatives having at least one intramolecular disulfide bond, and methods of preparation thereof. The invention also includes thiolated hyaluronan derivatives and salts thereof having at least one pendant thiol group or a modified pendant thiol group, and methods of preparation thereof. An example of a modified pendant thiol group is a sulfhydryl group linked to a small molecule such as a bioactive agent, for example a drug or pharmaceutically active moiety. A hyaluronan derivative having a sulfhydryl group linked to a pharmaceutically active moiety is useful as a sustained or controlled release drug delivery vehicle. Compositions containing the hyaluronan derivatives of the invention can reversibly viscosify in vivo or in vitro, in response to mild changes in condition, and are thus useful in ophthalmic surgery and in tissue engineering.Type: GrantFiled: February 21, 2002Date of Patent: September 16, 2003Assignee: Anika Therapeutics, Inc.Inventors: Paul C. A. Bulpitt, Charles H. Sherwood, Khalid K. Sadozai
-
Patent number: 6548081Abstract: The present invention relates to a composite and a method for reducing post-operative adhesion of tissues. The composite includes a biocompatible, biodegradable support, and a water-insoluble hyaluronic acid derivative at the support. The hyaluronic acid derivative includes an N-acylurea that results from cross-linking by the reaction of hyaluronic acid with a multifunctional carbodiimide. Optionally, a monocarbodiimide also may be employed. A pharmaceutically-active molecule may be added to the N-acylurea derivative of hyaluronic acid. Although the composite includes material that prevents adhesion between tissues, in order to reduce the need for suturing when the composite is being used during a surgical procedure, a material that enhances adhesion of the composite to tissues may be applied to a surface of the composite.Type: GrantFiled: May 22, 2001Date of Patent: April 15, 2003Assignee: Anika Therapeutics, Inc.Inventors: Khalid K. Sadozai, Jing-wen Kuo, Charles H. Sherwood
-
Publication number: 20020128512Abstract: The present invention relates to biscarbodiimides, thiourea derivatives, urea derivatives, and cross-linked hyaluronan derivatives having at least one intramolecular disulfide bond, and methods of preparation thereof. The invention also includes thiolated hyaluronan derivatives and salts thereof having at least one pendant thiol group or a modified pendant thiol group, and methods of preparation thereof. An example of a modified pendant thiol group is a sulfhydryl group linked to a small molecule such as a bioactive agent, for example a drug or pharmaceutically active moiety. A hyaluronan derivative having a sulfhydryl group linked to a pharmaceutically active moiety is useful as a sustained or controlled release drug delivery vehicle. Compositions containing the hyaluronan derivatives of the invention can reversibly viscosify in vivo or in vitro, in response to mild changes in condition, and are thus useful in ophthalmic surgery and in tissue engineering.Type: ApplicationFiled: February 21, 2002Publication date: September 12, 2002Applicant: Anika Therapeutics, Inc.Inventors: Paul C. A. Bulpitt, Charles H. Sherwood, Khalid K. Sadozai
-
Publication number: 20020071855Abstract: The present invention relates to a composite and a method for reducing post-operative adhesion of tissues. The composite includes a biocompatible, biodegradable support, and a water-insoluble hyaluronic acid derivative at the support. The hyaluronic acid derivative includes an N-acylurea that results from cross-linking by the reaction of hyaluronic acid with a multifunctional carbodiimide. Optionally, a monocarbodiimide also may be employed. A pharmaceutically-active molecule may be added to the N-acylurea derivative of hyaluronic acid. Although the composite includes material that prevents adhesion between tissues, in order to reduce the need for suturing when the composite is being used during a surgical procedure, a material that enhances adhesion of the composite to tissues may be applied to a surface of the composite.Type: ApplicationFiled: May 22, 2001Publication date: June 13, 2002Applicant: Anika Therapeutics, IncInventors: Khalid K. Sadozai, Jing-wen Kuo, Charles H. Sherwood
-
Patent number: 5895610Abstract: The polymethyl methacrylate (PMMA) or copolymer thereof used to produce one-piece intraocular lenses is modified by a compression molding process to produce a much tougher material with improved mechanical properties. The process takes material in rod form and compresses into lens blanks. The molded lens blanks receive little or no compression strain in the center 4 mm optic zone. The compression is limited to the periphery region outside the center 4 mm zone. The intraocular lens fabricated from the molded lens blank exhibits greatly increased haptic mechanical properties and resistance to breakage.Type: GrantFiled: September 30, 1997Date of Patent: April 20, 1999Assignee: Iolab CorporationInventors: Shiao H. Chang, Charles H. Sherwood, Bruce A. Tunberg, Paul D. Rice, Walker L. Gordy
-
Patent number: 5674284Abstract: The polymethyl methacrylate (PMMA) or copolymer thereof used to produce one-piece intraocular lenses is modified by a compression molding process to produce a much tougher material with improved mechanical properties. The process takes material in rod form and compresses into lens blanks. The molded lens blanks receive little or no compression strain in the center 4 mm optic zone. The compression is limited to the periphery region outside the center 4 mm zone. The intraocular lens fabricated from the molded lens blank exhibits greatly increased haptic mechanical properties and resistance to breakage.Type: GrantFiled: February 26, 1996Date of Patent: October 7, 1997Assignee: Iolab CorporationInventors: Shiao H. Chang, Charles H. Sherwood, Bruce A. Tunberg, Paul D. Rice, Walker L. Gordy
-
Patent number: 5582778Abstract: An improved intraocular lens has at least one filamentary haptic composed of a continuous matrix material interspersed with a toughening amount of discrete particles of a multistage, sequentially produced elastomeric polymer. An improved process for preparing a single-piece intraocular lens involves preparing a composite lens blank by molding pellets composed of a continuous polymeric material interspersed with particles of a multistage, sequentially produced elastomeric polymer about a central optic lens core so as to produce a single lens blank having a toughened annular region surrounding the central optic region, and then machining at least one filamentary haptic from the toughened annular region to prepare the lens.Type: GrantFiled: August 31, 1994Date of Patent: December 10, 1996Assignee: Iolab CorporationInventors: Charles H. Sherwood, Shiao H. Chang
-
Patent number: 5282853Abstract: An improved intraocular lens is disclosed with at least one filamentary haptic composed of a continuous matrix material interspersed with a toughening amount of discrete particles of a multistage, sequentially produced elastomeric polymer. An improved process for preparing a single-piece intraocular lens is also disclosed. The process involves preparing a composite lens blank by molding pellets composed of a continuous polymeric material interspersed with particles of a multistage, sequentially produced elastomeric polymer about a central optic lens core so as to produce a single lens blank having a toughened annular region surrounding the central optic region, and then machining at least one filamentary haptic from the toughened annular region to prepare the lens.Type: GrantFiled: September 29, 1992Date of Patent: February 1, 1994Assignee: Iolab CorporationInventors: Charles H. Sherwood, Shiao H. Chang
-
Patent number: 4540625Abstract: A flexible, air permeable composite highly effective as a highly absorbent fiber filter, suitable for high throughput, low pressure drop applications. The composites and filters use a non-woven fabric substrate, in conjunction with organic polymer fibers, such as polypropylene fibers, formed in-situ from a solvent solution of the polymer, with solid particles such as carbon particles interstitially positioned within the mass, and forming a unique microstructure by the interaction of the flexible non-woven fibers and the polymer fibers. A method of entrapping small sorptive particles within such filters is also provided.Type: GrantFiled: January 9, 1984Date of Patent: September 10, 1985Assignee: Hughes Aircraft CompanyInventor: Charles H. Sherwood